Literature DB >> 7814488

Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

F Barchiesi1, A L Colombo, D A McGough, M G Rinaldi.   

Abstract

A comparative study of broth macro- and microdilution methods for susceptibility testing of fluconazole, itraconazole, flucytosine, and amphotericin B was conducted with 273 yeasts. The clinical isolates included 100 Candida albicans, 28 Candida tropicalis, 25 Candida parapsilosis, 15 Candida lusitaniae, 15 Candida krusei, 50 Cryptococcus neoformans var. neoformans, 25 Torulopsis (Candida) glabrata, and 15 Trichosporon beigelii strains. Both methods were performed according to the National Committee for Clinical Laboratory Standards' (NCCLS) recommendations (document M27-P). For fluconazole, itraconazole, and flucytosine, the endpoint was the tube that showed 80% growth inhibition compared with the growth control for the macrodilution method and the well with slightly hazy turbidity (score 1) compared with the growth control for the microdilution method. For amphotericin B, the endpoint was the tube and/or well in which there was absence of growth. For the reference macrodilution method, the MICs were determined after 48 h of incubation for Candida spp., T. glabrata, and T. beigelii and after 72 h for C. neoformans var. neoformans. For the microdilution method, either the first-day MICs (24 h for all isolates other than C. neoformans and 48 h for C. neoformans var. neoformans) or the second-day MICs (48 and 72 h, respectively) were evaluated. The agreement within one doubling dilution of the macrodilution reference for all drugs was higher with the second-day MICs than with the first-day MICs for the microdilution test for most of the tested strains. General agreement was 92% for fluconazole, 85.7% for itraconazole, 98.3% for flucytosine, and 96.4% for amphotericin B. For C. neoformans var. neoformans and T. beigelii, the agreement of the first-day reading was higher than that of the second-day reading for fluconazole (94 versus 92%, respectively, for C. neoformans var. neoformans, and 86.7 versus 80%, respectively, for T. beigelii). Our studies indicate that the microdilution technique performed following the NCCLS guidelines with a second-day reading is a valid alternative method for testing fluconazole, itraconazole, flucytosine, and amphotericin B against these eight species of yeasts.

Entities:  

Mesh:

Year:  1994        PMID: 7814488      PMCID: PMC264090          DOI: 10.1128/jcm.32.10.2494-2500.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

Review 2.  Standardization of antifungal susceptibility testing.

Authors:  J N Galgiani; M G Rinaldi; A M Polak; M A Pfaller
Journal:  J Med Vet Mycol       Date:  1992

Review 3.  Antifungal susceptibility testing. Current state of technology, limitations, and standardization.

Authors:  M A Pfaller; M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1993-06       Impact factor: 5.982

4.  Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

Authors:  M A Pfaller; C Grant; V Morthland; J Rhine-Chalberg
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

5.  In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.

Authors:  T Peng; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Authors:  M L Cameron; W A Schell; S Bruch; J A Bartlett; H A Waskin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

7.  Improved medium for fluconazole susceptibility testing of Candida albicans.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

8.  Fluconazole-resistant Candida albicans.

Authors:  D J Boken; S Swindells; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1993-12       Impact factor: 9.079

9.  Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis.

Authors:  M A Pfaller; J Rhine-Chalberg; S W Redding; J Smith; G Farinacci; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

10.  Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole.

Authors:  E Bart-Delabesse; P Boiron; A Carlotti; B Dupont
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

View more
  33 in total

1.  Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.

Authors:  B A Arthington-Skaggs; M Motley; D W Warnock; C J Morrison
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions.

Authors:  W R Kirkpatrick; J L Lopez-Ribot; R K McAtee; T F Patterson
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy.

Authors:  D Arzeni; M Del Poeta; O Simonetti; A M Offidani; L Lamura; M Balducci; N Cester; A Giacometti; G Scalise
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

4.  Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.

Authors:  M H Nguyen; C Y Yu
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

5.  Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study.

Authors:  E J Anaissie; V L Paetznick; L G Ensign; A Espinel-Ingroff; J N Galgiani; C A Hitchcock; M LaRocco; T Patterson; M A Pfaller; J H Rex; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

Authors:  F Barchiesi; L Falconi Di Francesco; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

7.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

8.  Cryptococcosis in AIDS.

Authors:  P Imwidthaya; N Poungvarin
Journal:  Postgrad Med J       Date:  2000-02       Impact factor: 2.401

9.  Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test.

Authors:  J van Eldere; L Joosten; V Verhaeghe; I Surmont
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing.

Authors:  M A Pfaller; S Arikan; M Lozano-Chiu; Y Chen; S Coffman; S A Messer; R Rennie; C Sand; T Heffner; J H Rex; J Wang; N Yamane
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.